Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone as adjunctive therapy in MDD
NCT04985942Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lumateperone 42 mg with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Day 43. Started Jul 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04985942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985942.